Search

Your search keyword '"Sathekge, Mike M."' showing total 362 results
Start Over Author "Sathekge, Mike M."
362 results on '"Sathekge, Mike M."'

4. Radiotherapy and theranostics: a Lancet Oncology Commission

Author

Abdel-Wahab, May, Giammarile, Francesco, Carrara, Mauro, Paez, Diana, Hricak, Hedvig, Ayati, Nayyereh, Li, Jing Jing, Mueller, Malina, Aggarwal, Ajay, Al-Ibraheem, Akram, Alkhatib, Sondos, Atun, Rifat, Bello, Abubakar, Berger, Daniel, Delgado Bolton, Roberto C, Buatti, John M, Burt, Graeme, Bjelac, Olivera Ciraj, Cordero-Mendez, Lisbeth, Dosanjh, Manjit, Eichler, Thomas, Fidarova, Elena, Gondhowiardjo, Soehartati, Gospodarowicz, Mary, Grover, Surbhi, Hande, Varsha, Harsdorf-Enderndorf, Ekaterina, Herrmann, Ken, Hofman, Michael S, Holmberg, Ola, Jaffray, David, Knoll, Peter, Kunikowska, Jolanta, Lewis, Jason S, Lievens, Yolande, Mikhail-Lette, Miriam, Ostwald, Dennis, Palta, Jatinder R, Peristeris, Platon, Rosa, Arthur A, Salem, Soha Ahmed, dos Santos, Marcos A, Sathekge, Mike M, Shrivastava, Shyam Kishore, Titovich, Egor, Urbain, Jean-Luc, Vanderpuye, Verna, Wahl, Richard L, Yu, Jennifer S, Zaghloul, Mohamed Saad, Zhu, Hongcheng, and Scott, Andrew M

Published
2024
Full Text
View/download PDF

7. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Author

Sathekge, Mike M, Lawal, Ismaheel O, Bal, Chandrasekhar, Bruchertseifer, Frank, Ballal, Sajana, Cardaci, Giuseppe, Davis, Cindy, Eiber, Mathias, Hekimsoy, Türkay, Knoesen, Otto, Kratochwil, Clemens, Lenzo, Nat P, Mahapane, Johncy, Maserumule, Letjie C, Mdlophane, Amanda H, Mokoala, Kgomotso M G, Ndlovu, Honest, Pant, Vineet, Rathke, Hendrik, Reed, Janet, Sen, Ishita B, Singh, Aviral, Sood, Ashwani, Tauber, Robert, Thakral, Parul, Yadav, Madhav Prasad, and Morgenstern, Alfred

Published
2024
Full Text
View/download PDF

12. Targeted Alpha Therapy in Cancer Management: Therapeutic Prospects of Nuclear Medicine in Oncology

Author

Mdanda, Sipho, primary, Mdlophane, Amanda, additional, Ndlovu, Honest, additional, Ramonaheng, Keamogetswe, additional, Qebetu, Milani, additional, Mahapane, Johncy, additional, Kgatle, Mankgopo, additional, Mzizi, Yonwaba, additional, Sebatana, Reabetswe, additional, Cele, Zamani E. D., additional, Zeevaart, Jan Rijn, additional, and Sathekge, Mike M., additional

Published
2023
Full Text
View/download PDF

13. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Author

Lawal, Ismaheel O., Morgenstern, Alfred, Vorster, Mariza, Knoesen, Otto, Mahapane, Johncy, Hlongwa, Khanyisile N., Maserumule, Letjie C., Ndlovu, Honest, Reed, Janet D., Popoola, Gbenga O., Mokoala, Kgomotso M. G., Mdlophane, Amanda, Bruchertseifer, Frank, and Sathekge, Mike M.

Published
2022
Full Text
View/download PDF

25. Evaluation of [ 68 Ga]Ga-DOTA-AeK as a Potential Imaging Tool for PET Imaging of Cell Wall Synthesis in Bacterial Infections.

Author

Koatale, Palesa C., Welling, Mick M., Mdanda, Sipho, Mdlophane, Amanda, Takyi-Williams, John, Durandt, Chrisna, van den Bout, Iman, Cleeren, Frederik, Sathekge, Mike M., and Ebenhan, Thomas

Subjects
BACTERIAL cell walls, POSITRON emission tomography, ESCHERICHIA coli, RADIOCHEMICAL purification, GRAM-negative bacteria
Abstract

The ability of bacteria to recycle exogenous amino acid-based peptides and amino sugars for peptidoglycan biosynthesis was extensively investigated using optical imaging. In particular, fluorescent AeK–NBD was effectively utilized to study the peptidoglycan recycling pathway in Gram-negative bacteria. Based on these promising results, we were inspired to develop the radioactive AeK conjugate [68Ga]Ga-DOTA-AeK for the in vivo localization of bacterial infection using PET/CT. An easy-to-implement radiolabeling procedure for DOTA-AeK with [68Ga]GaCI3 followed by solid-phase purification was successfully established to obtain [68Ga]Ga-DOTA-AeK with a radiochemical purity of ≥95%. [68Ga]Ga-DOTA-AeK showed good stability over time with less protein binding under physiological conditions. The bacterial incorporation of [68Ga]Ga-DOTA-AeK and its fluorescent Aek-NBD analog were investigated in live and heat-killed Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). Unfortunately, no conclusive in vitro intracellular uptake of [68Ga]Ga-DOTA-AeK was observed for E. coli or S. aureus live and heat-killed bacterial strains (p > 0.05). In contrast, AeK-NBD showed significantly higher intracellular incorporation in live bacteria compared to the heat-killed control (p < 0.05). Preliminary biodistribution studies of [68Ga]Ga-DOTA-AeK in a dual-model of chronic infection and inflammation revealed limited localization at the infection site with non-specific accumulation in response to inflammatory markers. Finally, our study demonstrates proof that the intracellular incorporation of AeK is necessary for successful bacteria-specific imaging using PET/CT. Therefore, Ga-68 was not a suitable radioisotope for tracing the bacterial uptake of AeK tripeptide, as it required chelation with a bulky metal chelator such as DOTA, which may have limited its active membrane transportation. An alternative for optimization is to explore diverse chemical structures of AeK that would allow for radiolabeling with 18F or 11C. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. [ 18 F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology.

Author

Ndlovu, Honest, Lawal, Ismaheel O., Mdanda, Sipho, Kgatle, Mankgopo M., Mokoala, Kgomotso M. G., Al-Ibraheem, Akram, and Sathekge, Mike M.

Subjects
POLY ADP ribose, POLY(ADP-ribose) polymerase, RADIOACTIVE tracers, HOMOLOGOUS recombination, TRIPLE-negative breast cancer, CLINICAL medicine
Abstract

Including poly(ADP-ribose) polymerase (PARP) inhibitors in managing patients with inoperable tumors has significantly improved outcomes. The PARP inhibitors hamper single-strand deoxyribonucleic acid (DNA) repair by trapping poly(ADP-ribose)polymerase (PARP) at sites of DNA damage, forming a non-functional "PARP enzyme–inhibitor complex" leading to cell cytotoxicity. The effect is more pronounced in the presence of PARP upregulation and homologous recombination (HR) deficiencies such as breast cancer-associated gene (BRCA1/2). Hence, identifying HR-deficiencies by genomic analysis—for instance, BRCA1/2 used in triple-negative breast cancer—should be a part of the selection process for PARP inhibitor therapy. Published data suggest BRCA1/2 germline mutations do not consistently predict favorable responses to PARP inhibitors, suggesting that other factors beyond tumor mutation status may be at play. A variety of factors, including tumor heterogeneity in PARP expression and intrinsic and/or acquired resistance to PARP inhibitors, may be contributing factors. This justifies the use of an additional tool for appropriate patient selection, which is noninvasive, and capable of assessing whole-body in vivo PARP expression and evaluating PARP inhibitor pharmacokinetics as complementary to the currently available BRCA1/2 analysis. In this review, we discuss [18F]Fluorine PARP inhibitor radiotracers and their potential in the imaging of PARP expression and PARP inhibitor pharmacokinetics. To provide context we also briefly discuss possible causes of PARP inhibitor resistance or ineffectiveness. The discussion focuses on TNBC, which is a tumor type where PARP inhibitors are used as part of the standard-of-care treatment strategy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Tuberculosis

Author

Ankrah, Alfred O., Glaudemans, Andor W.J.M., Maes, Alex, Van de Wiele, Christophe, Dierckx, Rudi A.J.O., Vorster, Mariza, and Sathekge, Mike M.

Published
2018
Full Text
View/download PDF

38. Correlation between [68Ga]Ga-FAPI-46 PET Imaging and HIF-1α Immunohistochemical Analysis in Cervical Cancer: Proof-of-Concept

Author

Mokoala, Kgomotso M. G., primary, Lawal, Ismaheel O., additional, Maserumule, Letjie C., additional, Bida, Meshack, additional, Maes, Alex, additional, Ndlovu, Honest, additional, Reed, Janet, additional, Mahapane, Johncy, additional, Davis, Cindy, additional, Van de Wiele, Christophe, additional, Popoola, Gbenga, additional, Giesel, Frederik L., additional, Vorster, Mariza, additional, and Sathekge, Mike M., additional

Published
2023
Full Text
View/download PDF

42. Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.

Author

Ndlovu, Honest, Lawal, Ismaheel O., Mokoala, Kgomotso M. G., and Sathekge, Mike M.

Subjects
DRUG target, BREAST cancer, BREAST, PHENOTYPIC plasticity, POLY(ADP-ribose) polymerase, SPATIAL variation
Abstract

Breast cancer is the most frequently diagnosed cancer and leading cause of cancer-related deaths worldwide. Timely decision-making that enables implementation of the most appropriate therapy or therapies is essential for achieving the best clinical outcomes in breast cancer. While clinicopathologic characteristics and immunohistochemistry have traditionally been used in decision-making, these clinical and laboratory parameters may be difficult to ascertain or be equivocal due to tumor heterogeneity. Tumor heterogeneity is described as a phenomenon characterized by spatial or temporal phenotypic variations in tumor characteristics. Spatial variations occur within tumor lesions or between lesions at a single time point while temporal variations are seen as tumor lesions evolve with time. Due to limitations associated with immunohistochemistry (which requires invasive biopsies), whole-body molecular imaging tools such as standard-of-care [18F]FDG and [18F]FES PET/CT are indispensable in addressing this conundrum. Despite their proven utility, these standard-of-care imaging methods are often unable to image a myriad of other molecular pathways associated with breast cancer. This has stimulated interest in the development of novel radiopharmaceuticals targeting other molecular pathways and processes. In this review, we discuss validated and potential roles of these standard-of-care and novel molecular approaches. These approaches' relationships with patient clinicopathologic and immunohistochemical characteristics as well as their influence on patient management will be discussed in greater detail. This paper will also introduce and discuss the potential utility of novel PARP inhibitor-based radiopharmaceuticals as non-invasive biomarkers of PARP expression/upregulation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results